Opportunstic Hepatitis C Virus Treatment (Opportuni-C)
Primary Purpose
Hepatitis C, Substance Use Disorders
Status
Completed
Phase
Not Applicable
Locations
Norway
Study Type
Interventional
Intervention
Opportunstic treatment
Standard of care
Sponsored by
About this trial
This is an interventional health services research trial for Hepatitis C
Eligibility Criteria
Inclusion criteria
- Above 18 years of age
- HCV RNA positive
- Inpatient at participating ward
- Signed informed consent must be obtained and documented according to national and local regulations
Exclusion criteria:
- Pregnancy or breastfeeding.
- In involuntarily health care.
- Ongoing treatment of hepatitis C.
- Current participation in another trial that might affect the current study.
- Any reason why, in the opinion of the investigator, the patient should not participate (e.g. not able to comply with study procedures).
Sites / Locations
- AkershusUH
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Standard of care
Opportunistic treatment
Arm Description
Hospitalised patients with hep C are referred to the outpatient clinic at the medical department following discharge.
Hospitalised patients with hep C are opportunistically and immediately treated when hospitalized for acute care in psychiatric, addiction treatment or somatic wards
Outcomes
Primary Outcome Measures
Treatment completion
Proportion in each arm who have been dispensed the last 28 days package of HCV treatment
Secondary Outcome Measures
Sustained virological response
HCV RNA undetetctable 12 weeks after end of treatment
Reinfection
A HCV RNA strain not present at baseline is detected during or after treatment
End of treatment response
Proportion in each arm who have undetectable HCV RNA at the end of treatment
Full Information
NCT ID
NCT04220645
First Posted
October 1, 2019
Last Updated
December 7, 2022
Sponsor
University Hospital, Akershus
1. Study Identification
Unique Protocol Identification Number
NCT04220645
Brief Title
Opportunstic Hepatitis C Virus Treatment
Acronym
Opportuni-C
Official Title
Opportunistic Treatment of Hepatitis C Virus Infection (OPPORTUNI-C): A Pragmatic Clinical Trial of Immediate Versus Outpatient Treatment Initiation Among Hospitalized Patients
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
October 1, 2019 (Actual)
Primary Completion Date
December 31, 2021 (Actual)
Study Completion Date
June 30, 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University Hospital, Akershus
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The project will assess the effect of opportunistically treating hepatitis C virus (HCV) infection immediately when HCV-infected people who inject drugs are hospitalized for acute care in psychiatric, interdisciplinary specialized drug treatment or somatic wards. We will compare this approach with the current standard of care (SOC), which is referral to the outpatient clinic at the medical department following discharge.
Detailed Description
The overall objective is to show that opportunistic and immediate administration of HCV treatment is more efficient compared to referral-based SOC. The specific objectives are: 1) to compare the intervention and SOC groups with regards to treatment completion, treatment uptake and virologic response ; 2) to assess the rate of reinfection after successful HCV treatment; and 3) to assess the frequency of resistant associated substitutions before and after virologic treatment failure.
We will use a stepped wedge design and include patients in 7 clusters
Following randomization of the cluster to the immediate treatment, physicians at the participating wards will be notified in writing that for the next time period patients diagnosed with HCV infection should be treated immediately. In addition, lectures presenting the opportunistic approach will be given and the Department of Microbiology will add a brief text to the result of HCV RNA testing reminding about the opportunistic approach. In the medical and the psychiatric departments, consultants from the departments of infectious diseases or gastroenterology will prescribe immediate treatment. In the departments that provide addiction treatment, local physicians will prescribe treatment. Treatment will be prescribed in accordance with current Norwegian treatment recommendations. The intensity of care after discharge will be individualized at the discretion of the treating physician.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatitis C, Substance Use Disorders
7. Study Design
Primary Purpose
Health Services Research
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Pragmatic clinical trial. Cluster randomised with stepped wedge design
Masking
None (Open Label)
Allocation
Randomized
Enrollment
218 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Standard of care
Arm Type
Active Comparator
Arm Description
Hospitalised patients with hep C are referred to the outpatient clinic at the medical department following discharge.
Arm Title
Opportunistic treatment
Arm Type
Experimental
Arm Description
Hospitalised patients with hep C are opportunistically and immediately treated when hospitalized for acute care in psychiatric, addiction treatment or somatic wards
Intervention Type
Other
Intervention Name(s)
Opportunstic treatment
Intervention Description
opportunistically treating HCV infection immediately when hep C patients are hospitalized for acute care in psychiatric, addiction treatment or somatic wards
Intervention Type
Other
Intervention Name(s)
Standard of care
Intervention Description
Referral at discharge
Primary Outcome Measure Information:
Title
Treatment completion
Description
Proportion in each arm who have been dispensed the last 28 days package of HCV treatment
Time Frame
12 weeks
Secondary Outcome Measure Information:
Title
Sustained virological response
Description
HCV RNA undetetctable 12 weeks after end of treatment
Time Frame
24 weeks
Title
Reinfection
Description
A HCV RNA strain not present at baseline is detected during or after treatment
Time Frame
Two years
Title
End of treatment response
Description
Proportion in each arm who have undetectable HCV RNA at the end of treatment
Time Frame
12 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion criteria
Above 18 years of age
HCV RNA positive
Inpatient at participating ward
Signed informed consent must be obtained and documented according to national and local regulations
Exclusion criteria:
Pregnancy or breastfeeding.
In involuntarily health care.
Ongoing treatment of hepatitis C.
Current participation in another trial that might affect the current study.
Any reason why, in the opinion of the investigator, the patient should not participate (e.g. not able to comply with study procedures).
Facility Information:
Facility Name
AkershusUH
City
Lørenskog
State/Province
Select A State Or Province
ZIP/Postal Code
0278
Country
Norway
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
32539853
Citation
Midgard H, Finbraten AK, Malme KB, Berg-Pedersen RM, Tanum L, Olsen IC, Bjornestad R, Dalgard O. Opportunistic treatment of hepatitis C virus infection (OPPORTUNI-C): study protocol for a pragmatic stepped wedge cluster randomized trial of immediate versus outpatient treatment initiation among hospitalized people who inject drugs. Trials. 2020 Jun 15;21(1):524. doi: 10.1186/s13063-020-04434-8.
Results Reference
derived
Learn more about this trial
Opportunstic Hepatitis C Virus Treatment
We'll reach out to this number within 24 hrs